PitchSend

Investor Presentaiton

Novo Nordisk Annual Report 2023 Introducing Novo Nordisk Strategic Aspirations Risks Management Consolidated statements Additional information 29 29 Patent status for products with marketing authorisation DIABETES The patent expiry dates for products marketed by Novo Nordisk are shown in the tables on the right. The dates provided are for expiry in the US, China, Japan and Europe of patents on the active ingredient, unless otherwise indicated, and include actual and estimated extensions of patent term, when applicable. For several products, in addition to the active ingredient patent, Novo Nordisk holds other patents on manufacturing processes, formulations or uses that may be relevant for exclusivity beyond the expiration of the active ingredient patent. Furthermore, regulatory data protection and/or orphan exclusivity may apply. Product Human insulin and Modern insulins³ OBESITY RARE DISEASE US China Japan Europe² Expired Expired Expired Expired Product SaxendaⓇ US Expired China Japan Europe² Expired Expired Expired Product US China Japan WegovyⓇ 2032 2026 2031 2031 Norditropin® (SimpleXxⓇ) NovoSeven® Expired Expired Expired Europe² Expired Expired Expired Expired Expired VictozaⓇ4 Expired Expired Expired Expired Tresiba® 2029 2024 2027 2028 RyzodegⓇ 2029 2024 20245 2028 XultophyⓇ 2029 2024 20245 2028 Fiasp® 20306 20306 20306 20306 NovoEight® Refixia® (REBINYN®) EsperoctⓇ 2028 2027 No No No patent patent patent 2032 No patent 2027 2032 2029 2034 2034 VagifemⓇ Expired 10 mcg No patent Expired Expired Ozempic® 2032 2026 2031 2031 Rybelsus® 2032 2026 2031 2031 1. This overview does not include products whose sales represent less than 0.5% of Novo Nordisk's total sales. 2. Patent status varies from country to country. The figures in the table are based on Germany. 3. Modern insulins are NovoRapid (NovoLog®), Novo Mix 30 (NovoLog Mix 70/30), Levemir. 4. We have granted and pending patents covering the Victoza formulation. These patents generally expire in November 2024, except for the US where the formulation patent expires in February 2026. 5. Patent term extension until 2027 may apply. 6. Formulation patent; active ingredient patent has expired.

View entire presentation